Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study tracks kidney Drug's exit route in dialysis patients

NCT ID NCT06877247

Knowledge-focused Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This completed Phase 1 study looked at how a radioactive form of the drug SHR6508 is processed and eliminated in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. The main goal was to measure how much radioactivity ends up in urine and stool, and to identify the drug's breakdown products in the blood. This is a basic science study to understand the drug's journey through the body, not a test of whether it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[14C] SHR6508 Injection

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

5 people

The number who actually took part.

Started

Dec 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be able and willing to provide a written informed consent form. 2. Male subjects and postmenopausal women. 3. Meet the Body Mass Index (BMI) standard. Exclusion Criteria: 1. Subjects with a history of cardiovascular diseases. 2. Subjects with gastrointestinal diseases. 3. Subjects with a history of surgery. 4. Subjects with a history of blood loss. 5. Abnormal blood pressure. 6. Be allergic to a drug ingredient or component. 7. Subject with a history of alcohol abuse and drug abuse 8. The investigators determined that other conditions were inappropriate for participation in this clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Secondary hyperparathyroidism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

secondary hyperparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Secondary hyperparathyroidism

Contacts and locations

Locations

  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province)

    Jinan, Shandong, 250014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.